Article History
Accepted: 26 September 2023
First Online: 9 November 2023
Competing interests
: B.P.V. has acted as an adviser of AAA, Astellas Pharma, Bayer, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Merck, MSD, Novartis and Pfizer; has been an invited speaker for Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, EUSA Pharma, Janssen, Merck, MSD, Pfizer and Roche; and has received travel support from Merck and Pfizer. J.B. has acted as a consultant and/or adviser of Astellas Pharma, AstraZeneca/MedImmune, Bristol-Myers Squibb, Genentech, Merck, Pierre Fabre, Pfizer and Takeda; has received research funding from Pfizer/EMD Serono, Millennium and Sanofi and trial sponsorship from Associació per a la Recerca Oncológia (APRO); has received royalties from UpToDate; owns stocks in Rainier Therapeutics; and declares a non-financial interest as President of APRO. R.N. declares no competing interests.